



## Commercial/Healthcare Exchange PA Criteria

*Effective: December 14, 2018*

**Prior Authorization:** Vizimpro

**Products Affected:** Vizimpro (dacomitinib)

**Medication Description:**

Dacomitinib is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. As a kinase inhibitor, dacomitinib irreversibly inhibits the EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation).

**Covered Uses:** First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test

**Exclusion Criteria:**

1. Pediatric patients less than 18 years of age.

**Required Medical Information:**

1. Diagnosis
2. Confirmation of a known sensitizing EGFR mutation (i.e. exon 19 deletions or exon 21 (L858R) substitution mutations) as detected by an FDA-approved test (e.g. cobas® EGFR Mutation Test v2)

**Age Restrictions:** 18 years of age and older

**Prescriber Restrictions:** Prescribed by, or in consultation with, an oncologist.

**Coverage Duration:**

Initial: 12 months

Continuation: 3 years

**Other Criteria:**

- A. Patient has a diagnosis of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations; **AND**
- B. Vizimpro will be used as a single agent therapy for recurrent or metastatic disease.

**References:**

1. Vizimpro [package insert]. NY, NY; Pfizer; September 2018.

Last Rev. July 1, 2019



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

**Policy Revision history**

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	12/14/2018
2	Update	Added continuation coverage duration of 3 years	Coverage Duration	7/1/2019